Revolution Medicines (NASDAQ:RVMD) Stock Falls 4.7% – Here’s What Happened

Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) dropped 4.7% during mid-day trading on Wednesday. The company traded as low as $181.01 and last traded at $184.00. Approximately 649,969 shares traded hands during trading, a decline of 77% from the average daily volume of 2,799,531 shares. The stock had previously closed at $193.06.

Recent Revolution Medicines Headlines

Investors following RVMD have been watching these headlines:

• Positive Sentiment: HC Wainwright raised its earnings estimates across multiple quarters and for 2026 and 2027, including forecasting a return to positive full-year EPS in 2027. The firm reiterated its Buy rating and $350 price target. MarketBeat analyst estimates
• Positive Sentiment: Zacks reported a consensus price target implying about 33% upside and noted that improving earnings estimate revisions could support near-term sentiment. It cautioned that price targets alone have limited predictive value. Zacks analyst outlook
• Neutral Sentiment: A short-interest report lists zero shares sold short and a 0.0-day days-to-cover ratio, despite describing short interest as having increased. The figures appear inconsistent, so this data may not provide a reliable signal about positioning.

Analyst Ratings Changes

A number of equities analysts recently commented on RVMD shares. Morgan Stanley assumed coverage on shares of Revolution Medicines in a research note on Thursday, September 10th. They issued an “overweight” rating and a $255.00 price objective for the company. Bank of America decreased their target price on Revolution Medicines from $265.00 to $264.00 and set a “buy” rating for the company in a research report on Friday, October 9th. William Blair started coverage on Revolution Medicines in a report on Friday, October 16th. They set an “outperform” rating on the stock. Stifel Nicolaus upped their price target on Revolution Medicines from $215.00 to $230.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Finally, Piper Sandler increased their price objective on Revolution Medicines from $210.00 to $222.00 and gave the stock an “overweight” rating in a research note on Thursday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Revolution Medicines presently has an average rating of “Moderate Buy” and a consensus price target of $263.15.

Revolution Medicines Price Performance

The stock has a market capitalization of $39.49 billion, a PE ratio of -20.07 and a beta of 1.44. The company has a quick ratio of 8.34, a current ratio of 8.36 and a debt-to-equity ratio of 0.44. The stock’s 50-day moving average is $196.48 and its 200 day moving average is $158.35.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, November 4th. The company reported ($1.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.35) by $0.45. The company had revenue of $197.56 million during the quarter, compared to analysts’ expectations of $25.58 million. During the same quarter in the previous year, the company earned ($1.61) EPS. As a group, equities analysts predict that Revolution Medicines, Inc. will post -7.68 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Alan Sandler sold 6,309 shares of the stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $202.14, for a total transaction of $1,275,301.26. Following the completion of the sale, the insider directly owned 52,559 shares in the company, valued at approximately $10,624,276.26. This trade represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Stephen Kelsey sold 92,531 shares of Revolution Medicines stock in a transaction on Friday, September 11th. The shares were sold at an average price of $202.36, for a total value of $18,724,573.16. Following the sale, the insider directly owned 291,876 shares of the company’s stock, valued at approximately $59,064,027.36. The trade was a 24.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 290,991 shares of company stock valued at $59,422,765 in the last three months. Company insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Revolution Medicines

Several large investors have recently made changes to their positions in RVMD. Burkett Financial Services LLC acquired a new position in Revolution Medicines in the third quarter worth approximately $27,000. Contravisory Investment Management Inc. bought a new position in Revolution Medicines during the second quarter valued at approximately $32,000. ABS Investment Management LLC acquired a new stake in Revolution Medicines in the second quarter valued at approximately $337,104,000. Johnson Financial Group Inc. acquired a new stake in Revolution Medicines in the second quarter valued at approximately $37,000. Finally, Mather Group LLC. acquired a new stake in Revolution Medicines in the third quarter valued at approximately $41,000. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.